Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Cryoport (NASDAQ:CYRX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Volatility & Risk
Madrigal Pharmaceuticals has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Madrigal Pharmaceuticals and Cryoport, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 2 | 10 | 0 | 2.69 |
| Cryoport | 0 | 3 | 3 | 0 | 2.50 |
Valuation & Earnings
This table compares Madrigal Pharmaceuticals and Cryoport”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $76.81 million | 99.58 | -$373.63 million | ($25.08) | -13.98 |
| Cryoport | $233.26 million | 1.64 | -$99.59 million | ($3.67) | -2.11 |
Cryoport has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Cryoport, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Madrigal Pharmaceuticals and Cryoport’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | N/A | -71.78% | -53.25% |
| Cryoport | -76.48% | -15.55% | -7.41% |
Institutional & Insider Ownership
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 10.1% of Cryoport shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Cryoport beats Madrigal Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Cryoport
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
